Cargando…

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?

We conducted a prospective observational study of fit adults aged 60 to 75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics, or therapy-related MDS) or standard r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abel, Gregory A., Kim, Haesook T., Hantel, Andrew, Steensma, David P., Stone, Richard, Habib, Anand, Ho, Vincent T., Wadleigh, Martha, El-Jawahri, Areej, Alyea, Edwin P., DeAngelo, Daniel, Koreth, John, Antin, Joseph H., Soiffer, Robert J., Cutler, Corey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035144/ https://www.ncbi.nlm.nih.gov/pubmed/33204012 http://dx.doi.org/10.1038/s41375-020-01092-2

Ejemplares similares

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
por: Kekre, Natasha, et al.
Publicado: (2017)

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome
por: Brown, Jennifer R., et al.
Publicado: (2012)

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
por: Kim, Haesook T., et al.
Publicado: (2021)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
por: Whangbo, Jennifer S., et al.
Publicado: (2022)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma
por: Abou-Nassar, Karim E., et al.
Publicado: (2011)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results
por: Koreth, John, et al.
Publicado: (2018)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia
por: El‐Jawahri, Areej, et al.
Publicado: (2018)

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
por: Maurer, Katie, et al.
Publicado: (2021)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes
por: Armand, Philippe, et al.
Publicado: (2009)

Myelodysplastic syndromes current treatment algorithm 2018
por: Steensma, David P.
Publicado: (2018)

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults
por: Politikos, Ioannis, et al.
Publicado: (2015)

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation
por: Karantanos, Theodoros, et al.
Publicado: (2019)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
por: Hantel, Andrew, et al.
Publicado: (2021)

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome
por: Dillon, Laura W., et al.
Publicado: (2021)

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease
por: Donato, Veronica, et al.
Publicado: (2022)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic
por: Raman, Hari S., et al.
Publicado: (2021)

MON-347 Bilateral Adrenal Hemorrhage in a Patient with Myelodysplastic Syndrome and Clostridium Difficile Infection
por: Cutler, Jason, et al.
Publicado: (2019)

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
por: Ma, Xiaomei, et al.
Publicado: (2018)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
por: Li, L, et al.
Publicado: (2014)

Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
por: Weeks, Lachelle D., et al.
Publicado: (2022)

Randomized Study of enterade(®) to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: De Filipp, Zachariah, et al.
Publicado: (2021)

Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation
por: Dong, Jing, et al.
Publicado: (2023)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
por: Shimony, Shai, et al.
Publicado: (2023)

Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies
por: Liu, Michael A, et al.
Publicado: (2016)

A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: The PATH proof-of-concept trial
por: Amonoo, Hermioni L., et al.
Publicado: (2021)

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials
por: DeFilipp, Zachariah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sth8pj2evha3em4jie2kaicj92